Last update 04 Nov 2024

Fosaprepitant Dimeglumine

Last update 04 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Emend For Injection, Emend IV, fosaprepitant

+ [18]

Target

NK1R

Mechanism

NK1R antagonists(Neurokinin 1 receptor antagonists)

Therapeutic Areas

Other Diseases

Active Indication

NauseaVomitingChemotherapy-induced nausea and vomiting

Inactive Indication

Germ Cell and Embryonal NeoplasmsHydrocephalus, Endocardial Fibroelastosis, and CataractsMetastatic melanoma+ [4]

Originator Organization

Merck & Co., Inc.

Active Organization

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co. Ltd.

+ [4]

Inactive Organization

Merck Sharp & Dohme Corp.

Nanjing Westcom Biotechnology Co Ltd

Drug Highest PhaseApproved

First Approval Date

EU (11 Jan 2008),

Chemotherapy-induced nausea and vomiting

RegulationPriority Review (CN)

Structure

Molecular FormulaC30H39F7N5O11P

InChIKeyUGJUJYSRBQWCEK-GGXTVIBHSA-N

CAS Registry265121-04-8

Clinical Trials associated with Fosaprepitant Dimeglumine

NCT06382012 / RecruitingPhase 2/3IIT

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.

Start Date01 Oct 2024

Sponsor / Collaborator

Montefiore Medical Center

ChiCTR2400088071 / SuspendedPhase 4IIT

The Effect of Fosaprepitant on Postoperative Delirium and Sleep Quality in Elderly Gynecological Laparoscopic Surgery Patients: A Prospective Randomized Controlled Study

Start Date10 Aug 2024

Sponsor / Collaborator-

CTRI/2023/12/060941 / Not yet recruitingPhase 3

Anti-Emetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant for Children and Adolescents Receiving Moderately Emetogenic Chemotherapy: An Investigator-Initiated, Double-blinded, Superiority, Phase III Randomized Controlled Trial. - CIVIC MAN

Start Date01 Feb 2024

Sponsor / Collaborator

Cancer Institute (WIA)

100 Clinical Results associated with Fosaprepitant Dimeglumine

100 Translational Medicine associated with Fosaprepitant Dimeglumine

100 Patents (Medical) associated with Fosaprepitant Dimeglumine

246

Literatures (Medical) associated with Fosaprepitant Dimeglumine

01 Nov 2024·JOURNAL OF PHARMACOLOGICAL SCIENCES

Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets

Article

Author: Nagata, Masanori ; Nakazawa, Taisuke ; Ugawa, Tohru ; Yamanaka, Yosuke ; Kinugasa, Fumitaka ; Kajikawa, Satoru ; Haggerty, Gillian ; Akuzawa, Shinobu ; Weng, Jane ; Fushiki, Hiroshi ; Suzuki, Hiroshi ; Sawamoto, Taiji

Claudin-18 splice variant 2 (CLDN18.2), a tight junction protein, is a highly cell type-specific antigen that is expressed by differentiated gastric mucosa cells. The expression of CLDN18.2 in gastric mucosa cells may be retained upon malignant transformation and is displayed on the surface of several tumors, including gastric/gastroesophageal junction adenocarcinoma. Zolbetuximab is a genetically engineered, highly purified chimeric (mouse/human IgG1) antibody directed against CLDN18.2. Nausea and vomiting were observed as adverse events of zolbetuximab. To investigate the mechanism of nausea and vomiting in humans, we evaluated emesis (retching and vomiting) and conducted histopathologic assessment in ferrets after the administration of zolbetuximab. Emesis was frequently observed in all ferrets treated with zolbetuximab in the first hour after administration. Histopathologic assessment revealed the surface of the gastric mucosa was the primary site of emesis-associated tissue damage. The effect of antiemetics (dexamethasone, ondansetron, fosaprepitant, and olanzapine) on emesis induced by zolbetuximab was investigated. Fosaprepitant showed suppressive effects on emesis, and use of dexamethasone or concomitant use of fosaprepitant with other antiemetics tended to alleviate gastric tissue damage. The onset of emesis in humans receiving zolbetuximab may be associated with damage in the gastric mucosa, and antiemetics may mitigate gastrointestinal adverse events.

01 Nov 2024·TOXICOLOGY AND APPLIED PHARMACOLOGY

Fosaprepitant improves cyclophosphamide-induced bladder damage by alleviating inflammatory response in mice

Article

Author: Yesilbas Aksel, Yaren ; Aksel, Yaren Yeşilbaş ; Barut, Elif Nur ; Engin, Seckin

Inhibition of inflammatory process is a key therapeutic target for the treatment of interstitial cystitis (IC). Recent reports indicate that neurokinin 1 receptor (NK1R) antagonists have beneficial roles in inflammatory-based diseases. Herein, we investigate the protective effects of fosaprepitant (FOS), a NK1R antagonist, in cyclophosphamide (CP)-induced cystitis. The cystitis model was established multiple CP (80 mg/kg; i.p.) injection one day apart, and mice were treated with FOS (20 and 60 mg/kg/day; i.p.) for seven consecutive days. Detrusor contractility, vesical vascular permeability, myeloperoxidase (MPO) activity and protein expression levels of the TLR4 pathway were evaluated in mice bladder. Carbachol and electric field stimulation-evoked contractions of detrusor strips were significantly increased in CP-treated mice, which was significantly attenuated by FOS (60 mg/kg/day) treatment (p<0.001, p<0.05). Notably, vesical vascular permeability was markedly impaired in CP-induced cystitis, that was restored by FOS (60 mg/kg/day) treatment (p<0.01). MPO activity was significantly increased in cystitis group whereas FOS (20 and 60 mg/kg/day) treatment remarkably suppressed MPO activity in bladder tissue (p<0.001). Although TLR4 expression increased with cystitis, MyD88 and p-NFκB^Ser536/total NFκB did not change, FOS (20 and 60 mg/kg/day) treatment caused a dramatic decrease in TLR4 expression (p<0.001), indicating the anti-inflammatory effect of FOS. In conclusion, FOS improved detrusor overactivity and inflammatory response by inhibiting MPO activity and TLR4 expression, resulting in functional and histological recovery in CP-induced cystitis.

01 Sep 2024·ECOLOGICAL APPLICATIONS

Functional responses of understory plants to natural disturbance‐based management in eastern and western Canada

Article

Author: Noualhaguet, Marion ; Fenton, Nicole J. ; Nock, Charles A. ; Macdonald, S. Ellen ; Aubin, Isabelle ; Work, Timothy T.

Abstract:

Natural disturbance‐based management (NDBM) is hypothesized to maintain managed forest ecosystem integrity by reducing differences between natural and managed forests. The effectiveness of this approach often entails local comparisons of species composition or diversity for a variety of biota from managed and unmanaged forests. Understory vegetation is regularly the focus of such comparison because of its importance in nutrient cycling, forest regeneration, and for wildlife. However, larger scale comparisons between regions with distinct species assemblages may require a trait‐based approach to better understand understory responses to disturbance. We compared the long‐term effects of retention harvesting on understory vegetation in two large experimental study sites located in eastern and western regions of the Canadian boreal forest. These sites included the Sylviculture en Aménagement Forestier Ecosystémique (SAFE) experiment and the Ecosystem Management Emulating Natural Disturbance (EMEND) experiment, located in the eastern and western regions of Canada, respectively. EMEND and SAFE share common boreal understory species but have distinct tree communities, soils, and climate. Both experiments were designed to evaluate how increasing tree retention after harvest affects biodiversity. Here, we examined taxonomic richness, functional diversity, and functional composition (using community trait mean values) of understory plant communities, and also examine intraspecific trait variability (ITV) for five species common and abundant in both experiments. We observed the limited impacts of retention level on richness, functional diversity, and functional composition of understory plants 20 years postharvest. However, ITV of leaf morphological traits varied between retention levels within each experiment, depending on the species identity. Common species had different functional responses to retention level, showing species‐specific reactions to environmental variation. Our result suggests that understory plant communities in the boreal forest achieve resilience to disturbance both in terms of interspecific and intraspecific functional trait diversity. Such diversity may be key to maintaining understory biodiversity in the face of future disturbances and environmental change. Our results reveal the significance of ITV in plant communities for understanding responses to forest harvesting and the importance of choosing appropriate traits when studying species responses to the environment.

News (Medical) associated with Fosaprepitant Dimeglumine

10 Oct 2024

·www.prnewswire.com

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

SAN DIEGO, Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not require additional dilution with IV fluids in what may be a time of critical shortage. As widely reported, the potential disruption in the supply of intravenously administered fluids is a result of the temporary closure of a major suppliers' manufacturing site in Marion, North Carolina which was impacted by Hurricane Helene. The Marion facility is believed to supply up to 60% of the IV fluid market in the U.S. "In the wake of Hurricane Helene, and with the recently announced potential supply disruption for IV fluids, Heron has received outreach from several health systems preparing to maintain continuity of care," said Craig Collard, Chief Executive Officer of Heron. "Our team is committed to ensuring timely delivery of our products throughout the U.S. during the potential shortage of IV fluids as we understand the importance of preventing CINV and PONV for both patients and providers." CINVANTI, SUSTOL, and APONVIE are available through major wholesalers and specialty distributors, and further information can be obtained by calling the Company's information line at 844-HERON11 (844-437-6611). About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND® capsules. Aprepitant (including its prodrug, fosaprepitant) is a single-agent NK1 RA to significantly reduce nausea and vomiting in both the acute phase (0–24 hours after chemotherapy) and the delayed phase (24–120 hours after chemotherapy). The FDA-approved dosing administration included in the U.S. prescribing information for CINVANTI include 100 mg or 130 mg administered as a 30-minute IV infusion or a 2-minute IV injection. Please see full prescribing information at . About SUSTOL for CINV Prevention SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron's Biochronomer® drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL's efficacy and safety in more than 2,000 patients with cancer. SUSTOL's efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0–24 hours after chemotherapy) and delayed phase (24–120 hours after chemotherapy). Please see full prescribing information at . About APONVIE for Postoperative Nausea and Vomiting (PONV) APONVIE is a substance NK1 Receptor Antagonist (RA), indicated for the prevention of PONV in adults. Delivered via a 30-second IV push, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of therapeutic drug levels. APONVIE is the same formulation as Heron's approved drug product CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023. Please see full prescribing information at . About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the potential market opportunities for APONVIE®, CINVANTI® and SUSTOL®. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 SOURCE Heron Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalClinical Result

23 Sep 2024

·www.businesswire.com

Avenacy to Share Company’s Year One Progress at CPHI Milan 2024

SCHAUMBURG, Ill.--( BUSINESS WIRE )--Avenacy, a specialty pharmaceutical company focused on supplying critical medications, looks forward to celebrating its first year of growth and success since launching in October 2023. Backed by a robust global network of development and FDA-inspected contract manufacturing partners, Avenacy has already brought 13 injectable products to the U.S. market to address key gaps in the drug supply chain. “We are incredibly proud of the achievements and progress we have made at Avenacy since launching nearly a year ago as a trusted partner and provider of critical injectable medicines for the U.S. healthcare system,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “We have acted swiftly and decisively to bring over a dozen medications to the U.S. market to help meet the needs of patients, strengthened our financial position with the addition of esteemed pharmaceutical investor and businessman, Dr. Patrick Soon-Shiong, and built out our infrastructure and leadership to support scaling up our business. As we look to usher in the next phase of growth for Avenacy, we will remain steadfast in our goal of enhancing patient care and enabling access to safe, high-quality essential medications.” Through a rigorous and optimized selection process, Avenacy has launched thirteen products in the U.S. market, including: Melphalan Hydrochloride for Injection Bivalirudin for Injection Fosaprepitant for Injection Fulvestrant Injection Furosemide for Injection Desmopressin Acetate for Injection Eptifibatide for Injection Magnesium Sulfate in Water for Injection Isoproterenol Hydrochloride Injection, USP Tranexamic Acid Injection, USP Prochlorperazine Edisylate Injection, USP Palonosetron Hydrochloride Injection, USP Metoclopramide Injection, USP The Company is well-positioned to continue expanding its differentiated portfolio to meet the needs of today’s dynamic drug supply chain while ensuring quality of care to patients. All of Avenacy’s products feature unique packaging and labeling designed to assist healthcare providers with accurate medication selection, thereby supporting a reduction in administration errors and improper dosing. The Company also utilizes ready-to-use formulations of essential medications to help address dosing inaccuracies, enhance patient safety, and streamline efficiency – all with the ultimate goal of improving patient care. Avenacy will be sharing its first year progress, differentiated business model, and diverse partner network at this year’s CPHI 2024 Conference, taking place in Milan from October 8-10. During this time, the Company will be hosting meetings with potential partners, customers, and investors, as it seeks to expand its global presence and portfolio of critical injectable medicines. About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/ .

Executive Change

17 Sep 2024

·www.fiercebiotech.com

Drug based on anti-nausea agent reduces Alzheimer's-advancing astrocytes in mice, biotech says

In the hippocampus, one of the first brain regions usually damaged by Alzheimer’s disease, both 20-mg and 40-mg doses of Hoth Therapeutics' HT-ALZ reduced the percentage of astrocyte coverage compared to the control, according to the company. Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, neuron maintenance and many other functions. In Alzheimer’s disease, some astrocytes serve as celestial guardians that break down the amyloid beta protein plaques that build up in the brain; others, however, go rogue, actually secreting amyloid beta themselves.A drug candidate from Hoth Therapeutics, based on the anti-nausea agent aprepitant, reduced the brain area covered by astrocytes and improved cognitive function in a mouse model of Alzheimer’s, the company announced in a Sept. 17 release.“The reductions in astrocyte activity and the corresponding improvements in cognitive function observed with HT- ALZ give us confidence as we move forward in our development process,” Hoth CEO Robb Knie said in the release.In the hippocampus, one of the first brain regions usually damaged by Alzheimer’s, both 20-mg and 40-mg doses of HT-ALZ reduced the percentage of astrocyte coverage compared to the control, the company said. A similar pattern was seen in the cortex, and the decrease in astrocytes corresponded with improved cognitive function, according to Hoth. HT-ALZ’s active ingredient is aprepitant, a molecule that binds to the neurokinin 1 receptor in the central nervous system and has been approved by the FDA since 2003. Aprepitant is sold by Merck as Emend to prevent nausea and vomiting in cancer patients undergoing chemotherapy.The reactive astrocytes that respond to Alzheimer’s and other diseases tend to be larger than normal astrocytes. In addition to some astrocytes secreting amyloid beta, the reactive cells also produce toxic byproducts as they work to break down amyloid beta into urea, which contributes to disease progression.Hoth is currently exploring whether treatment with HT-ALZ changes the size or total number of astrocytes, the company said. Early evidence suggests treated mice have fewer reactive astrocytes than control mice, the biotech said.HT-ALZ is being developed as an oral soluble film, according to Hoth’s website.

Drug Approval

100 Deals associated with Fosaprepitant Dimeglumine

External Link

KEGG	Wiki	ATC	Drug Bank
D06597	Fosaprepitant Dimeglumine	A04AD12	DB06717

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nausea	CN	Jiangsu Hansoh Pharmaceutical Co. Ltd.	29 Sep 2019
Vomiting	CN	Jiangsu Hansoh Pharmaceutical Co. Ltd.	29 Sep 2019
Chemotherapy-induced nausea and vomiting	EU	Merck Sharp & Dohme BV	11 Jan 2008
Chemotherapy-induced nausea and vomiting	IS	Merck Sharp & Dohme BV	11 Jan 2008
Chemotherapy-induced nausea and vomiting	LI	Merck Sharp & Dohme BV	11 Jan 2008
Chemotherapy-induced nausea and vomiting	NO	Merck Sharp & Dohme BV	11 Jan 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hydrocephalus, Endocardial Fibroelastosis, and Cataracts	Phase 3	CN	Jiangsu Hansoh Pharmaceutical Co. Ltd.	06 Feb 2015
Nausea and vomiting	Phase 3	CN	Jiangsu Hansoh Pharmaceutical Co. Ltd.	06 Feb 2015
Postoperative Nausea and Vomiting	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jul 2005
Non-Small Cell Lung Cancer	Phase 2	US	Merck Sharp & Dohme Corp.	01 Apr 2015
Metastatic melanoma	Phase 2	US	Merck Sharp & Dohme Corp.	01 Sep 2013
Metastatic Renal Cell Carcinoma	Phase 2	US	Merck Sharp & Dohme Corp.	01 Sep 2013
Germ Cell and Embryonal Neoplasms	Phase 2	US	Merck Sharp & Dohme Corp.	01 Jan 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2024	Not Applicable	-	-	Fosaprepitant	thvnvtdivn(ejainlpxsu) = qnphobmhet sswguqwulm (vysbrmqygp )	Negative	24 May 2024
NCT03237611 (CTgov)	Phase 2	Chemotherapy-induced nausea and vomiting	15	Ondansetron 16 MG+Aprepitant 125 mg+Dexamethasone+Fosaprepitant 115 MG	teuxlxtaim(gtbbphjtkj) = ixrfuozjsq lktofglnbq (dfrhenujto, mghvgqpovj - vkqebfgxxx) View more	-	13 Nov 2023
NCT05564286 (Pubmed \| Support Care Cancer)	Phase 3	-	116	Fosaprepitant, tropisetron, and dexamethasone	qyozhvfecv(nbtoeaibdi) = Fosaprepitant was well tolerated as the incidences of adverse events in the two groups were comparable pavwcgpgbs (kshfgivcxg ) View more	Positive	01 Nov 2023
				Tropisetron plus dexamethasone
FDA Manual	Not Applicable	Chemotherapy-induced nausea and vomiting	2,322	FOCINVEZ+ondansetron+dexamethasone (Intravenous)	nixekzxwxt(wdvvcadrwr) = hefzrianlq mmjxiexoyy (pwelryionn ) View more	Positive	22 Aug 2023
				Aprepitant+ondansetron+dexamethasone (Oral)	nixekzxwxt(wdvvcadrwr) = akkpnbnotn mmjxiexoyy (pwelryionn ) View more
FDA Manual	Not Applicable	Chemotherapy-induced nausea and vomiting	1,000	FOCINVEZ+ondansetron+dexamethasone (Intravenous)	dnzrmfdbod(oibcifaneq) = snodatisph mollhgvfem (janjgenyto ) View more	Positive	22 Aug 2023
				ondansetron+dexamethasone	dnzrmfdbod(oibcifaneq) = qrkpzknyba mollhgvfem (janjgenyto ) View more
NCT03578081 (CTgov)	Phase 3	Nausea \| Chemotherapy-induced nausea and vomiting \| Neoplasms ... View more	690	Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine))	yrbmxlmviw(dbpvymqose) = lbcgzfufhw rjtyxualua (guqhphnfxy, udwrzvnajk - kvmxmvysjt) View more	-	08 May 2023
				Placebo+Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone (Arm II (Placebo, Olanzapine))	yrbmxlmviw(dbpvymqose) = jequtoghzj rjtyxualua (guqhphnfxy, etfrznmznm - rxaaqasmxl) View more
NCT03197064 (CTgov)	Phase 4	Postoperative Nausea and Vomiting	11	Fosaprepitant 150 mg	irnxvfegqe(wnmrolqfpr) = piakxqretg spdmyktphe (sslwcdorvm, wjllnoobqj - wlvdtrbkfd) View more	-	18 Jul 2022
NCT04054193 (0517-045 \| MK-0517-045, CTgov)	Phase 4	Nausea \| Chemotherapy-induced nausea and vomiting \| Vomiting	103	5-HT3 antagonist+Dexamethasone+Fosaprepitant Dimeglumine	mcalacgxtz(sreezkwzqq) = irrapknmxa ysydraevnc (ngyjnyclxg, caxkoetipq - xydwwhhang) View more	-	23 Sep 2021
CTRI/2017/02/007925 (ASCO2018)	Phase 3	Chemotherapy-induced nausea and vomiting	135	Fosaprepitant	ogmoseafjz(eiiruvftfr) = twsoomuqgt bugildzdio (qdxosrusdh ) View more	Positive	01 Jun 2018
				Placebo	ogmoseafjz(eiiruvftfr) = dwatimngig bugildzdio (qdxosrusdh ) View more
NCT01874119 (HDIL2/Emend, CTgov)	Phase 2	Metastatic Renal Cell Carcinoma \| Chemotherapy-induced nausea and vomiting \| Metastatic melanoma	13	Fosaprepitant (Fosaprepitant)	kzzrvtsdua(hkdnlrrgjz) = qaqjujbxzq ntnuywpxes (gmlkfpukag, ifgkabrimo - ogphuyidwv) View more	-	04 May 2018
				Fosaprepitant (Placebo)	kzzrvtsdua(hkdnlrrgjz) = bhalejhujk ntnuywpxes (gmlkfpukag, qmuhobrvgz - nohdmctglg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis